We are live on ! Find out more
TCM

TCG Crossover Management Portfolio holdings

AUM $4.16B
1-Year Est. Return 983.43%
This Fund
S&P 500
This Quarter Est. Return
+18.76%
1 Year Est. Return
+983.43%
3 Year Est. Return
+3,012.95%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.18B
AUM Growth
+$221M
Cap. Flow
+$85.7M
Cap. Flow %
7.26%
Top 10 Hldgs %
58.4%
Holding
38
New
6
Increased
2
Reduced
5
Closed
2

Top Buys

Rank Stock Value
1
XNCR icon
Xencor
XNCR
+$45.6M
2
FULC icon
Fulcrum Therapeutics
FULC
+$38.9M
3
THRD
Third Harmonic Bio
THRD
+$29.9M
4
MBX
MBX Biosciences
MBX
+$14.9M
5
GPCR icon
Structure Therapeutics
GPCR
+$14.2M

Top Sells

Rank Stock Value
1
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$41.8M
2
TARS icon
Tarsus Pharmaceuticals
TARS
+$9.12M
3
MLYS icon
Mineralys Therapeutics
MLYS
+$8.65M
4
CCCC icon
C4 Therapeutics
CCCC
+$5.9M
5
SLN
Silence Therapeutics
SLN
+$4.87M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CGON icon
1
CG Oncology
CGON
$6.59B
$138M 11.73%
3,670,206
– –
DYN icon
2
Dyne Therapeutics
DYN
$4.68B
$95.2M 8.07%
2,650,150
– –
COGT icon
3
Cogent Biosciences
COGT
$6.02B
$75.2M 6.37%
6,964,375
– –
ABVX
4
Abivax
ABVX
$9.89B
$69.8M 5.91%
6,056,596
– –
EWTX icon
5
Edgewise Therapeutics
EWTX
$4.64B
$56.4M 4.78%
2,112,984
-159,744
-7% -$3.18M
SLN
6
Silence Therapeutics
SLN
$834M
$55.2M 4.67%
3,033,560
-261,790
-8% -$4.87M
SVRA icon
7
Savara
SVRA
$1.08B
$52.4M 4.44%
12,362,205
– –
KROS icon
8
Keros Therapeutics
KROS
$219M
$51.1M 4.33%
879,344
– –
XNCR icon
9
Xencor
XNCR
$1.94B
$48.8M 4.14%
+2,427,138
New +$45.6M
TYRA icon
10
Tyra Biosciences
TYRA
$1.49B
$46.8M 3.96%
1,989,103
– –
GPCR icon
11
Structure Therapeutics
GPCR
$3.38B
$46.7M 3.95%
1,063,000
+368,453
+53% +$14.2M
OCUL icon
12
Ocular Therapeutix
OCUL
$2.28B
$46.3M 3.92%
5,319,148
– –
CNTA
13
DELISTED
Centessa Pharmaceuticals
CNTA
$46.2M 3.92%
2,890,816
– –
TRML
14
DELISTED
Tourmaline Bio
TRML
$38M 3.22%
1,477,593
– –
THRD
15
DELISTED
Third Harmonic Bio
THRD
$32.7M 2.77%
+2,415,000
New +$29.9M
ATXS
16
DELISTED
Astria Therapeutics
ATXS
$30.4M 2.58%
2,761,861
– –
MLYS icon
17
Mineralys Therapeutics
MLYS
$2.26B
$29.9M 2.53%
2,470,265
-714,920
-22% -$8.65M
KURA icon
18
Kura Oncology
KURA
$1.13B
$27.8M 2.36%
1,423,642
– –
SLNO
19
DELISTED
Soleno Therapeutics
SLNO
$27.8M 2.35%
550,000
– –
CMPS
20
Compass Pathways
CMPS
$1.9B
$24.3M 2.06%
3,858,000
– –
IRON icon
21
Disc Medicine
IRON
$3.07B
$23.9M 2.03%
486,957
– –
FULC icon
22
Fulcrum Therapeutics
FULC
$294M
$18.7M 1.59%
+5,250,000
New +$38.9M
MBX
23
MBX Biosciences
MBX
$3.03B
$16.9M 1.43%
+650,000
New +$14.9M
AMLX icon
24
Amylyx Pharmaceuticals
AMLX
$3.87B
$15M 1.27%
+4,643,812
New +$10.4M
ADVM
25
DELISTED
Adverum Biotechnologies
ADVM
$14.1M 1.19%
2,008,339
-1
-0% -$7
1
2

Similar funds

GCM
Gates Capital Management New York $4.16B AUM 21% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
CIC
Chilton Investment Company Stamford, Connecticut $4.17B AUM 1.75% 1-Year Est. Return
LWCA
Locust Wood Capital Advisers New York $4.15B AUM 31.06% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $4.15B AUM
CAM
Crake Asset Management London, United Kingdom $4.18B AUM 13.97% 1-Year Est. Return
JFG
JMG Financial Group Downers Grove, Illinois $4.14B AUM 21.49% 1-Year Est. Return

TCG Crossover Management's Q3 2024 Portfolio in Review

As of Q3 2024, TCG Crossover Management held 38 positions worth $1.18B, up 23% from $960M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

TCG Crossover Management deployed $85.7M of net new capital in Q3 2024, opening 6 new positions and adding to 2 existing holdings. Its largest new stake was Xencor: 2,427,138 shares worth $48.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Tarsus Pharmaceuticals, an estimated $9.12M trimmed.

  • TCG Crossover Management's largest Q3 2024 buy was Xencor: 2,427,138 shares worth $48.8M.
  • TCG Crossover Management added most to Structure Therapeutics in Q3 2024, an estimated $14.2M increase.
  • TCG Crossover Management's biggest Q3 2024 reduction was Tarsus Pharmaceuticals, cutting an estimated $9.12M.
  • TCG Crossover Management fully exited Madrigal Pharmaceuticals in Q3 2024, selling an estimated $41.8M.
  • TCG Crossover Management's ten largest holdings make up 58% of its $1.18B portfolio in Q3 2024.
  • TCG Crossover Management opened 6 new positions and closed 2 in Q3 2024.
  • TCG Crossover Management's portfolio value rose 23% quarter-over-quarter to $1.18B.

Based on TCG Crossover Management's 13F filing for Q3 2024, filed 14 Nov 2024.